The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Sep. 23, 2022
Applicant:

Werewolf Therapeutics, Inc., Cambridge, MA (US);

Inventors:

William Winston, West Newton, MA (US);

Daniel Hicklin, Boston, MA (US);

Jose Andres Salemeron-Garcia, Acton, MA (US);

Heather Brodkin, West Newton, MA (US);

Cynthia Seidel-Dugan, Belmont, MA (US);

Assignee:

Werewolf Therapeutics, Inc., Watertown, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/715 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 38/2013 (2013.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 38/208 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); A61K 47/6425 (2017.08); A61K 47/65 (2017.08); A61K 47/6813 (2017.08); A61K 47/6845 (2017.08); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C12N 15/63 (2013.01);
Abstract

The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g. a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.


Find Patent Forward Citations

Loading…